A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical modelsEric S. Lightcap, Dennis Huszar, Stephen Grossman et al.|Science Translational Medicine|2021Cited by 139
The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulationAkito Nakamura, Dennis Huszar|Blood|2022Cited by 69